학술논문

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, April 2023, 24(4):323-334)
Subject
Language
English
ISSN
14745488
14702045